[Radiotherapy for soft tissue sarcomas: Technical evolution and impact on clinical benefit].
The standard treatment for extremity soft tissue sarcomas is based on the association of surgery and radiotherapy. This strategy allows local control improvement with the risk of increased toxicity. There is therefore a growing interest to identify those patients who will benefit from radiotherapy and those who will have the same local control with surgery alone. Furthermore, the development of toxicity has been correlated with the extension of the irradiated volume and the volume receiving high doses. Technological development as intensity modulated radiotherapy and image-guided radiotherapy allows limited irradiated volume improving the protection of the organs at risk leading to clinical benefit improvement. Moreover, efforts are being done to improve local control for the patients at high risk of local relapse. In this paper, we discuss all these mentioned aspects.
Département de radiothérapie oncologique, institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France. Electronic address: carmen.llacer@icm.unicancer.fr.
C
C
Llacer-Moscardo
Département de radiothérapie oncologique, institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France.
C
C
Bourgier
Département de radiothérapie oncologique, institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France.
A
A
Morel
Département de radiothérapie oncologique, institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France.
P
P
Fenoglietto
Département de chirurgie oncologique, institut du cancer de Montpellier, 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France.
S
S
Carrère
Département d'oncologie médicale, institut du cancer de Montpellier, 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France.
N
N
Firmin
Département de radiothérapie oncologique, institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France.
D
D
Azria
D004487:Edema / Q000209:etiology; D050723:Fractures, Bone / Q000209:etiology; D006801:Humans; D000072662:Margins of Excision; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D018579:Patient Selection; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D061089:Radiotherapy, Image-Guided; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects; D012509:Sarcoma / Q000532:radiotherapy* / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000532:radiotherapy* / Q000601:surgery
Contrôle local; IMRT; Local control; RCMI; Sarcomes des tissus mous; Soft tissue sarcoma; Toxicity; Toxicité